Resolvyx Pharmaceuticals

... the end in inflammation

  • About Us
  • Products
  • Technology
  • News & Publications
  • Contact Us
  • Press Releases
  • News
  • Publications

Press Releases

07.03.08 - 

Resolvyx Scientific Advisors Publish First In-Vivo Data Showing Resolvins Suppress IL-23 and IL-17, Key Mediators of Inflammatory Disease

06.24.08 - 

FierceBiotech Names Resolvyx Pharmaceuticals as One of the "Fierce 15" Biotech Companies of 2008

05.01.08 - 

Resolvyx Compounds Show Promise In Treatment of Ocular Disease

04.24.08 - 

Resolvyx to Present Data on Novel Resolvin Drug Candidates for Eye Disease at ARVO Annual Meeting

04.22.08 - 

Resolvyx Pharmaceuticals Strengthens Its Board of Directors with Industry Leaders

04.22.08 - 

Resolvyx Pharmaceuticals Raises $25 Million in Series B Financing

04.01.08 - 

Resolvyx Pharmaceuticals Presents Data for Novel Resolvin Therapeutic at ACC

09.10.07 - 

Resolvyx Pharmaceuticals Hires James Nichols as EVP of Corporate Development

12.09.05 - 

Resolvyx Pharmaceuticals wins $17M in first-round funding

Resolvins modify function of several pathways in a "many-to-one" approach with a high potential for efficacy across different etiologies and pathologies

  • Home
  • Site Map
  • Contact Us
© 2008 Resolvyx Pharmaceuticals — All Rights Reserved. |
Created by PixelMEDIA, Inc.
  • Management Team
  • Board of Directors
  • Advisory Board
  • RX-10001
  • RX-10045
  • RX-20001
  • Press Releases
  • News
  • Publications
  • Directions
  • Career Opportunities